Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below.
Presentation details
Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Session Title: First-in-Human Phase I Clinical Trials 2
Session Date and Time: Tuesday 9 April 2024 9:00 AM – 12:30 PM
Location: San Diego Convention Center, San Diego CA USA
Abstract Presentation Number: CT188
First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust